The goal of this clinical trial is to evaluate the effect of Zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications. The worldwide disease burden is profound, with a global prevalence of over 1 billion, and approximately 9 million deaths attributed to hypertension annually.

The potential benefits to participants would be study-related medical care at no-cost and knowledge gained about their condition. On a wider scale, there may be general benefits to society because the investigational treatment may become a future treatment option.

To qualify for the study, you must be:

• Male or female adult 19 years of age or older
• History of cardiovascular (CV) disease, high CV risk, or Chronic Kidney Disease (CKD)
• Must be on stable therapy with 2 to 4 classes of antihypertensive medications
• Mean seated office SBP ≥140 mmHg and ≤170 mmHg
• 24-hour mean SBP ≥130 mmHg and ≤170 mmHg assessed by ABPM
• Other criteria may apply*

*There are multiple studies available to participate in and each may require different criteria to be approved as a participant.

To learn more about this trial and to find out if you qualify, please call 402.934.0044 or complete the form on our Contact page.